The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks like pretzel. The tube straightens while it is inserted by catheter into the ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at Jefferies raised the stock’s price target to $9 from 8 while reiterating a Buy ...

Bladder stones (vesical calculi) almost always form due to an underlying issue like urinary stasis, obstruction, or foreign bodies. High-risk populations include women with pelvic organ prolapse and ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...